Results 141 to 150 of about 26,086 (200)

Corrigendum to "Heterogeneous expression of predictive biomarkers PD-L1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: A challenge for clinical biomarker testing" [Neoplasia 38 (2023) 100884]. [PDF]

Neoplasia
Kolb T, Benckendorff J, Möller P, Barth TFE, Marienfeld RB.   +4 more
europepmc   +1 more source

T cell exhaustion in sepsis: mechanisms, biomarkers, and immune-reversal strategies. [PDF]

Front Immunol
Li D, Wang Y, Li J, Chen H, Cui Y, Xia W, Wang H.   +6 more
europepmc   +1 more source

Comment on Raineri et al. Memory Regulatory T Cells as a Biomarker of Early Type 1 Diabetes. [PDF]

Diabetes
Gootjes C, Nikolic T, Roep BO.
europepmc   +1 more source

Lineage-specific immune checkpoint dynamics define a context-dependent regulatory framework with translational relevance in human γδ T cells. [PDF]

J Transl Med
Corsale AM, Di Simone M, Cerapio JP, Lo Presti E, Pizzolato G, Avellone C, Dieli C, Marchiafava S, Di Paola L, Dieli F, Meraviglia S.   +10 more
europepmc   +1 more source

Plasticity and immune marker profiling of tumour- and ascites-derived microtumours in serous ovarian cancer: relevance for short-term culture models. [PDF]

Front Immunol
Hell L, Ding Y, Pellens C, Eylmann K, Rossberg M, Bokemeyer C, Kupper J, Schmalfeldt B, Brauneck F, Wellbrock J, Sturmheit T, Oliveira-Ferrer L.   +11 more
europepmc   +1 more source

AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer. [PDF]

J Immunother Cancer
Lu S, Yu Y, Zhang J, Wang Q, Cho EK, Zhao J, Kim SH, Lee Y, Clay TD, Yang TY, Chang GC, Yang H, Zuo Y, Liu R, Sun P, Kim HR.   +15 more
europepmc   +1 more source

Current Insights into the Role of Peripheral Blood Immune Cell Phenotypes in Resistance to Cancer Therapies. [PDF]

Oncol Res
Olaechea A, Camacho Rubio C, Gómez-Melero S.   +2 more
europepmc   +1 more source

Spatiotemporal dynamics of the tumor microenvironment in hepatocellular carcinoma during combination immunotherapy. [PDF]

Hepatol Commun
Iwasaki H, Itoh S, Toshida K, Mita J, Ishikawa T, Iseda N, Yugawa K, Yoshiya S, Motomura T, Toshima T, Aishima S, Oda Y, Yoshizumi T.   +12 more
europepmc   +1 more source

Restoring the CD226 in CD8⁺T cells overcomes TIGIT-refractory immunity in HER2⁺ breast cancer. [PDF]

Cell Death Dis
Zhang L, Li J, Xiu B, Zheng C, Zhang Q, Lu H, Wang Z, Shao Z, Xue J, Chi Y, Xiang D, Wu J.   +11 more
europepmc   +1 more source

Harnessing tumor immune checkpoints for autoimmune disease therapeutics. [PDF]

Front Immunol
Yang H, Zhang P, Wu Y, Xie N, Shen G.
europepmc   +1 more source